Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT

S. Fuji, K. Takano, Takehiko Mori, T. Eto, S. Taniguchi, K. Ohashi, H. Sakamaki, Y. Morishima, K. Kato, K. Miyamura, R. Suzuki, T. Fukuda

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

To elucidate the impact of pretransplant body mass index (BMI) on the clinical outcome, we performed a retrospective study with registry data including a total of 12 050 patients (age ≥18 years) who received allogeneic hematopoietic SCT (HSCT) between 2000 and 2010. Patients were stratified as follows: BMI<18.5 kg/m 2, Underweight, n=1791; 18.5≤BMI<25, Normal, n=8444; 25≤BMI<30, Overweight, n=1591; BMI≥30, Obese, n=224. The median age was 45 years (range, 18-77). A multivariate analysis showed that the risk of relapse was significantly higher in the underweight group and lower in the overweight and obese groups compared with the normal group (hazard ratio (HR), 1.16, 0.86, and 0.74, respectively). The risk of GVHD was significantly higher in the overweight group compared with the normal group. The risk of non-relapse mortality (NRM) was significantly higher in the overweight and obese group compared with the normal group (HR 1.19 and HR 1.43, respectively). The probability of OS was lower in the underweight group compared with the normal group (HR 1.10, P=0.018). In conclusion, pretransplant BMI affected the risk of relapse and NRM after allogeneic HSCT. Underweight was a risk factor for poor OS because of an increased risk of relapse. Obesity was a risk factor for NRM.

Original languageEnglish
Pages (from-to)1505-1512
Number of pages8
JournalBone Marrow Transplantation
Volume49
Issue number12
DOIs
Publication statusPublished - 2014 Dec 11

Fingerprint

Thinness
Body Mass Index
Recurrence
Mortality
Registries
Multivariate Analysis
Retrospective Studies
Obesity

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. / Fuji, S.; Takano, K.; Mori, Takehiko; Eto, T.; Taniguchi, S.; Ohashi, K.; Sakamaki, H.; Morishima, Y.; Kato, K.; Miyamura, K.; Suzuki, R.; Fukuda, T.

In: Bone Marrow Transplantation, Vol. 49, No. 12, 11.12.2014, p. 1505-1512.

Research output: Contribution to journalArticle

Fuji, S, Takano, K, Mori, T, Eto, T, Taniguchi, S, Ohashi, K, Sakamaki, H, Morishima, Y, Kato, K, Miyamura, K, Suzuki, R & Fukuda, T 2014, 'Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT', Bone Marrow Transplantation, vol. 49, no. 12, pp. 1505-1512. https://doi.org/10.1038/bmt.2014.178
Fuji, S. ; Takano, K. ; Mori, Takehiko ; Eto, T. ; Taniguchi, S. ; Ohashi, K. ; Sakamaki, H. ; Morishima, Y. ; Kato, K. ; Miyamura, K. ; Suzuki, R. ; Fukuda, T. / Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. In: Bone Marrow Transplantation. 2014 ; Vol. 49, No. 12. pp. 1505-1512.
@article{e2ccc8064a63400eae0a868be00ccf9f,
title = "Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT",
abstract = "To elucidate the impact of pretransplant body mass index (BMI) on the clinical outcome, we performed a retrospective study with registry data including a total of 12 050 patients (age ≥18 years) who received allogeneic hematopoietic SCT (HSCT) between 2000 and 2010. Patients were stratified as follows: BMI<18.5 kg/m 2, Underweight, n=1791; 18.5≤BMI<25, Normal, n=8444; 25≤BMI<30, Overweight, n=1591; BMI≥30, Obese, n=224. The median age was 45 years (range, 18-77). A multivariate analysis showed that the risk of relapse was significantly higher in the underweight group and lower in the overweight and obese groups compared with the normal group (hazard ratio (HR), 1.16, 0.86, and 0.74, respectively). The risk of GVHD was significantly higher in the overweight group compared with the normal group. The risk of non-relapse mortality (NRM) was significantly higher in the overweight and obese group compared with the normal group (HR 1.19 and HR 1.43, respectively). The probability of OS was lower in the underweight group compared with the normal group (HR 1.10, P=0.018). In conclusion, pretransplant BMI affected the risk of relapse and NRM after allogeneic HSCT. Underweight was a risk factor for poor OS because of an increased risk of relapse. Obesity was a risk factor for NRM.",
author = "S. Fuji and K. Takano and Takehiko Mori and T. Eto and S. Taniguchi and K. Ohashi and H. Sakamaki and Y. Morishima and K. Kato and K. Miyamura and R. Suzuki and T. Fukuda",
year = "2014",
month = "12",
day = "11",
doi = "10.1038/bmt.2014.178",
language = "English",
volume = "49",
pages = "1505--1512",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT

AU - Fuji, S.

AU - Takano, K.

AU - Mori, Takehiko

AU - Eto, T.

AU - Taniguchi, S.

AU - Ohashi, K.

AU - Sakamaki, H.

AU - Morishima, Y.

AU - Kato, K.

AU - Miyamura, K.

AU - Suzuki, R.

AU - Fukuda, T.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - To elucidate the impact of pretransplant body mass index (BMI) on the clinical outcome, we performed a retrospective study with registry data including a total of 12 050 patients (age ≥18 years) who received allogeneic hematopoietic SCT (HSCT) between 2000 and 2010. Patients were stratified as follows: BMI<18.5 kg/m 2, Underweight, n=1791; 18.5≤BMI<25, Normal, n=8444; 25≤BMI<30, Overweight, n=1591; BMI≥30, Obese, n=224. The median age was 45 years (range, 18-77). A multivariate analysis showed that the risk of relapse was significantly higher in the underweight group and lower in the overweight and obese groups compared with the normal group (hazard ratio (HR), 1.16, 0.86, and 0.74, respectively). The risk of GVHD was significantly higher in the overweight group compared with the normal group. The risk of non-relapse mortality (NRM) was significantly higher in the overweight and obese group compared with the normal group (HR 1.19 and HR 1.43, respectively). The probability of OS was lower in the underweight group compared with the normal group (HR 1.10, P=0.018). In conclusion, pretransplant BMI affected the risk of relapse and NRM after allogeneic HSCT. Underweight was a risk factor for poor OS because of an increased risk of relapse. Obesity was a risk factor for NRM.

AB - To elucidate the impact of pretransplant body mass index (BMI) on the clinical outcome, we performed a retrospective study with registry data including a total of 12 050 patients (age ≥18 years) who received allogeneic hematopoietic SCT (HSCT) between 2000 and 2010. Patients were stratified as follows: BMI<18.5 kg/m 2, Underweight, n=1791; 18.5≤BMI<25, Normal, n=8444; 25≤BMI<30, Overweight, n=1591; BMI≥30, Obese, n=224. The median age was 45 years (range, 18-77). A multivariate analysis showed that the risk of relapse was significantly higher in the underweight group and lower in the overweight and obese groups compared with the normal group (hazard ratio (HR), 1.16, 0.86, and 0.74, respectively). The risk of GVHD was significantly higher in the overweight group compared with the normal group. The risk of non-relapse mortality (NRM) was significantly higher in the overweight and obese group compared with the normal group (HR 1.19 and HR 1.43, respectively). The probability of OS was lower in the underweight group compared with the normal group (HR 1.10, P=0.018). In conclusion, pretransplant BMI affected the risk of relapse and NRM after allogeneic HSCT. Underweight was a risk factor for poor OS because of an increased risk of relapse. Obesity was a risk factor for NRM.

UR - http://www.scopus.com/inward/record.url?scp=84927174908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927174908&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.178

DO - 10.1038/bmt.2014.178

M3 - Article

VL - 49

SP - 1505

EP - 1512

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -